I am taking the liberty to repost information rece
Post# of 593
(Total Views: 284)
Posted On: 06/29/2022 9:27:08 AM
I am taking the liberty to repost information received from a poster on the other board. Kudos to rayinbrookly65!
UEEC: The fundamentals of this company remain solid; this assessment is not an opinion but is predicated on FACTS such as:
1. The promise of its proprietary clotting protocol, HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining approval to access the human surgical market. This unique and highly effective clotting agent was developed and is manufactured and marketed exclusively by United Health Products. The market for this clotting agent is assessed at $8 billion annually.
2. This company has a very favorable share structure for investors as enumerated below:
- Authorized Shares: 300,000,000 as of 06/28/2022
- Outstanding Shares: 229,877,509 as of 06/28/2022
- Restricted Shares: 84,980,391 as of 06/28/2022
- Unrestricted Shares: 144,897,118 as of 06/28/2022
- Held at DTC: 116,862,498 as of 06/28/2022
- Float: 99,945,675 as of 05/17/2016
3. Board members who have demonstrated their proficiency in a triad of disciplines:
a. Responsible, purposeful approach toward administration of the company's finances;
b. Remaining steadfast to the science in the research and development of Hemostyp; and
c, Proficiently navigating the steady progression in the bureaucratic Food and Drug Administration (FDA) Pre-Market Approval (PMA) process.
All these factors, which, again, are demonstrable FACTS and not the spin of opinion, are the reasons why I have remain invested in UEEC for nearly three years and will continue to do so as I am confident this stock will eclipse the $10 per share benchmark all those investors who have done their due diligence KNOW eventually will occur.
UEEC: The fundamentals of this company remain solid; this assessment is not an opinion but is predicated on FACTS such as:
1. The promise of its proprietary clotting protocol, HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining approval to access the human surgical market. This unique and highly effective clotting agent was developed and is manufactured and marketed exclusively by United Health Products. The market for this clotting agent is assessed at $8 billion annually.
2. This company has a very favorable share structure for investors as enumerated below:
- Authorized Shares: 300,000,000 as of 06/28/2022
- Outstanding Shares: 229,877,509 as of 06/28/2022
- Restricted Shares: 84,980,391 as of 06/28/2022
- Unrestricted Shares: 144,897,118 as of 06/28/2022
- Held at DTC: 116,862,498 as of 06/28/2022
- Float: 99,945,675 as of 05/17/2016
3. Board members who have demonstrated their proficiency in a triad of disciplines:
a. Responsible, purposeful approach toward administration of the company's finances;
b. Remaining steadfast to the science in the research and development of Hemostyp; and
c, Proficiently navigating the steady progression in the bureaucratic Food and Drug Administration (FDA) Pre-Market Approval (PMA) process.
All these factors, which, again, are demonstrable FACTS and not the spin of opinion, are the reasons why I have remain invested in UEEC for nearly three years and will continue to do so as I am confident this stock will eclipse the $10 per share benchmark all those investors who have done their due diligence KNOW eventually will occur.
(0)
(0)